Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility under the company's ShareReward Plan, filed in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions.
- Share Price: 1572.79 pence per Ordinary Share (transaction date: April 9, 2014).
- Transaction Type: Acquisition of Ordinary Shares via personal contribution and company matching elements of the ShareReward Plan.
Material Changes
The filing details the acquisition of shares by nine individuals, including Sir Andrew Witty, Mr S Dingemans, Mr S M Bicknell, Mr R G Connor, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte. Each individual acquired 8 Ordinary Shares through personal contribution and an additional 8 Ordinary Shares through the company matching element.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of director shareholdings.
Investor Verification Points
- Verify the total number of shares acquired by each named director (16 shares per person: 8 personal + 8 matched).
- Confirm the transaction price of 1572.79 pence per share against market data for April 9, 2014.
- Review the full terms of the ShareReward Plan to understand the matching contribution mechanics.